Related Experiment Video
Updated: Jun 14, 2025
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
Published on: February 24, 2014
A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)
Ener Cagri Dinleyici1, Ergin Ciftci2, Ayper Somer3
1Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkiye.
Abstract:
Neisseria meningitidis (Nm) remains a major global health concern, causing invasive meningococcal disease (IMD) with significant morbidity and mortality. Despite vaccination efforts, Nm serogroup prevalence and antibiotic resistance continue to evolve, necessitating ongoing surveillance and novel immunization strategies. This review aims to assess the role of MenACWY-TT, a quadrivalent meningococcal conjugate vaccine, in IMD prevention by evaluating its immunogenicity, safety, and real-world effectiveness. The objectives include analyzing its advantages over existing vaccines, identifying gaps in long-term immunity data, and assessing its potential integration into National Immunization Programs (NIPs). MenACWY-TT has demonstrated strong immunogenicity, a favorable safety profile, and ease of administration with its liquid, non-adjuvanted formulation. Real-world studies show high vaccine effectiveness and herd protection benefits. However, further research is needed to evaluate long-term immunity and efficacy in high-risk populations.
Insights
MenACWY-TT vaccine effectively prevents invasive meningococcal disease (IMD) by inducing strong immunity and offering herd protection. Further research on long-term immunity is recommended for high-risk groups.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Neisseria meningitidis (Nm) causes invasive meningococcal disease (IMD), a significant global health threat.
- Evolving serogroup prevalence and antibiotic resistance necessitate continuous surveillance and new vaccines.
- Current vaccination strategies require ongoing evaluation and improvement.
Purpose of the Study:
- To review the MenACWY-TT vaccine's role in preventing IMD.
- To evaluate its immunogenicity, safety, and real-world effectiveness.
- To identify advantages over existing vaccines and gaps in long-term immunity data.
Main Methods:
- Literature review of studies on MenACWY-TT vaccine.
- Analysis of immunogenicity, safety, and effectiveness data.
- Assessment of real-world evidence and herd protection benefits.
Main Results:
- MenACWY-TT demonstrates strong immunogenicity and a favorable safety profile.
- The vaccine is easy to administer due to its liquid, non-adjuvanted formulation.
- Real-world studies confirm high vaccine effectiveness and herd immunity.
Conclusions:
- MenACWY-TT is a valuable tool for IMD prevention.
- Further investigation into long-term immunity and efficacy in high-risk populations is warranted.
- The vaccine shows potential for integration into National Immunization Programs.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
